Literature DB >> 1689539

High-dose intravenous gamma globulin infusions in hemolytic-uremic syndrome: a preliminary report.

K J Sheth1, J C Gill, H E Leichter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1689539     DOI： 10.1001/archpedi.1990.02150270014009

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN： 0002-922X


× No keyword cloud information.
  5 in total

1.  Verocytotoxin producing Escherichia coli.

Authors:  M G Brook; B A Bannister
Journal:  BMJ       Date:  1991-10-05

2.  Differences in verotoxin neutralizing activity of therapeutic immunoglobulins and sera from healthy controls.

Authors:  M Bitzan; M Klemt; R Steffens; D E Müller-Wiefel
Journal:  Infection       Date:  1993 May-Jun       Impact factor: 3.553

3.  The use of intravenous gammaglobulin in the treatment of typical hemolytic uremic syndrome.

Authors:  W L Robson; G H Fick; T Jadavji; A K Leung
Journal:  Pediatr Nephrol       Date:  1991-05       Impact factor: 3.714

Review 4.  Evidence for the use of intravenous immunoglobulins--a review of the literature.

Authors:  Shaye Kivity; Uriel Katz; Natalie Daniel; Udi Nussinovitch; Neophytos Papageorgiou; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

5.  IgG Binds Escherichia coli Serine Protease EspP and Protects Mice From E. coli O157:H7 Infection.

Authors:  Ashmita Tontanahal; Vanessa Sperandio; Olga Kovbasnjuk; Sebastian Loos; Ann-Charlotte Kristoffersson; Diana Karpman; Ida Arvidsson
Journal:  Front Immunol       Date:  2022-02-18       Impact factor: 8.786
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.